0.8124 USD
+0 (+0.11%)
2.4303 USD
+1.62 (+199.15%)
Overall IVF gets a fundamental rating of 2 out of 10. We evaluated IVF against 185 industry peers in the Health Care Equipment & Supplies industry. IVF has a bad profitability rating. Also its financial health evaluation is rather negative. IVF is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year IVF has reported negative net income.
- In the past year IVF has reported a negative cash flow from operations.
- IVF had negative earnings in each of the past 5 years.
- IVF had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -155.09%, IVF is doing worse than 88.11% of the companies in the same industry.
- IVF has a worse Return On Equity (-499.38%) than 82.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -155.09% | ||
| ROE | -499.38% | ||
| ROIC | N/A |
ROA(3y)-109.72%
ROA(5y)-93.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- IVF has a Gross Margin of 39.17%. This is in the lower half of the industry: IVF underperforms 68.11% of its industry peers.
- In the last couple of years the Gross Margin of IVF has declined.
- IVF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.07%
GM growth 5Y-13.44%
2. Health
2.1 Basic Checks
- IVF does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, IVF has more shares outstanding
- The number of shares outstanding for IVF has been increased compared to 5 years ago.
- The debt/assets ratio for IVF is higher compared to a year ago.
2.2 Solvency
- IVF has an Altman-Z score of -8.60. This is a bad value and indicates that IVF is not financially healthy and even has some risk of bankruptcy.
- IVF's Altman-Z score of -8.60 is on the low side compared to the rest of the industry. IVF is outperformed by 77.30% of its industry peers.
- A Debt/Equity ratio of 0.31 indicates that IVF is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.31, IVF perfoms like the industry average, outperforming 49.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.6 |
ROIC/WACCN/A
WACC6.21%
2.3 Liquidity
- IVF has a Current Ratio of 0.12. This is a bad value and indicates that IVF is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 0.12, IVF is doing worse than 95.68% of the companies in the same industry.
- A Quick Ratio of 0.10 indicates that IVF may have some problems paying its short term obligations.
- With a Quick ratio value of 0.10, IVF is not doing good in the industry: 95.68% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.12 | ||
| Quick Ratio | 0.1 |
3. Growth
3.1 Past
- IVF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -808.80%.
- IVF shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.50%.
- The Revenue has been growing by 34.57% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-808.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.06%
Revenue 1Y (TTM)11.5%
Revenue growth 3Y16.23%
Revenue growth 5Y34.57%
Sales Q2Q%22.8%
3.2 Future
- Based on estimates for the next years, IVF will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.59% on average per year.
- Based on estimates for the next years, IVF will show a quite strong growth in Revenue. The Revenue will grow by 10.00% on average per year.
EPS Next Y92.84%
EPS Next 2Y39.17%
EPS Next 3Y23.45%
EPS Next 5Y13.59%
Revenue Next Year10.02%
Revenue Next 2Y10.01%
Revenue Next 3Y10%
Revenue Next 5Y10%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for IVF. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IVF. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- IVF's earnings are expected to grow with 23.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.17%
EPS Next 3Y23.45%
5. Dividend
5.1 Amount
- IVF does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.8124
+0 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-17 2025-11-17/bmo
Earnings (Next)04-28 2026-04-28/amc
Inst Owners11.54%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change-0.69%
Market Cap1.54M
Revenue(TTM)6.94M
Net Income(TTM)-29.21M
Analysts80
Price Target146.88 (17979.76%)
Short Float %N/A
Short Ratio0.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.08%
Min Revenue beat(2)-3.98%
Max Revenue beat(2)10.15%
Revenue beat(4)3
Avg Revenue beat(4)60.92%
Min Revenue beat(4)-3.98%
Max Revenue beat(4)236.57%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)700%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-700%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.26 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-644.61
EYN/A
EPS(NY)-23.76
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4.05
OCFYN/A
SpS3.67
BVpS3.09
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -155.09% | ||
| ROE | -499.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.17% | ||
| FCFM | N/A |
ROA(3y)-109.72%
ROA(5y)-93.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.07%
GM growth 5Y-13.44%
F-Score3
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 14.3% | ||
| Cap/Sales | 1.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.12 | ||
| Quick Ratio | 0.1 | ||
| Altman-Z | -8.6 |
F-Score3
WACC6.21%
ROIC/WACCN/A
Cap/Depr(3y)84.61%
Cap/Depr(5y)530.77%
Cap/Sales(3y)6.25%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-808.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.06%
EPS Next Y92.84%
EPS Next 2Y39.17%
EPS Next 3Y23.45%
EPS Next 5Y13.59%
Revenue 1Y (TTM)11.5%
Revenue growth 3Y16.23%
Revenue growth 5Y34.57%
Sales Q2Q%22.8%
Revenue Next Year10.02%
Revenue Next 2Y10.01%
Revenue Next 3Y10%
Revenue Next 5Y10%
EBIT growth 1Y-61.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.93%
OCF growth 3YN/A
OCF growth 5YN/A
INVO FERTILITY INC / IVF FAQ
What is the ChartMill fundamental rating of INVO FERTILITY INC (IVF) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IVF.
What is the valuation status of INVO FERTILITY INC (IVF) stock?
ChartMill assigns a valuation rating of 1 / 10 to INVO FERTILITY INC (IVF). This can be considered as Overvalued.
How profitable is INVO FERTILITY INC (IVF) stock?
INVO FERTILITY INC (IVF) has a profitability rating of 0 / 10.
Can you provide the financial health for IVF stock?
The financial health rating of INVO FERTILITY INC (IVF) is 1 / 10.